natgillin/translations-raw huggingface dataset:
Appropriate monitoring and dose adjustment may be necessary for drugs that are CYP3A4 substrates and have a narrow therapeutic index (including but not limited to alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, sirolimus and tacrolimus) when co-administered with nilotinib.
Nilotiniibiga koosmanustamisel võib olla vajalik CYP3A4 substraatide ja kitsa terapeutilise indeksiga ravimite (sealhulgas, ja mitte ainult, alfentaniil, tsüklosporiin, dihüdroergotamiin, ergotamiin, fentanüül, siroliimus ja takroliimus) asjakohane jälgimine ja annuse kohandamine.
Appropriate monitoring is advised.
Vajalik on patsiendi jälgimine.
appropriate monitoring of
vajalik, on siiski
Appropriate monitoring of serum digoxin levels is
Soovitatav on digoksiini plasmasisalduse sobiv jälgimine.
Appropriate monitoring should be implemented in dogs under stress (e.g. post- operative) or those with hypoadrenocorticism.
Hoolikalt tuleb jälgida koeri, kellel esineb stress (nt post-operatiivne) või hüpoadrenokortitsism.
Appropriate observation of patients for serotonin syndrome-like symptoms is advised.
Soovitatav on patsiente serotoniinisündroomi taoliste sümptomite suhtes asjakohaselt jälgida.
Appropriate observation of patients for serotonin syndrome-like symptoms is advised.
Soovitatav on patsiente sobival viisil jälgida serotoniinisündroomi sarnaste sümptomite suhtes.
Appropriate precautions (e.g. use of a condom) should be taken to prevent passing on the disease through sexual contact.
Te peate rakendama sobivaid ettevaatusmeetmeid (nt kasutama kondoomi), et vähendada riski nakatada teisi seksuaalkontaktil.
Appropriate precautions must be taken for women of child-bearing potential (see sections 4.3, 4.4 and 4.6).
Fertiilses eas naiste puhul tuleb kasutusele võtta sobivad ettevaatusabinõud (vt lõigud 4.3, 4.4 ja 4.6).
Appropriate preventive analgesia medicinal products must be administered.
Manustada tuleb ennetavaid valuvastaseid ravimeid.
Appropriate preventive analgesia medicinal products must be administered.
Manustada tuleb sobivaid ennetavaid valuvastaseid ravimeid.
Appropriate procedures for proper handling and disposal of cytotoxic medicines must be followed.
Tuleb järgida tsütotoksilise ravimi õige ja sobiva käsitsemise ja hävitamise toiminguid.
Appropriate prophylactic measures including aggressive hydration and anti-hyperuricaemic therapy (such as allopurinol or rasburicase) should be used for the prevention and treatment of TLS during BLINCYTO treatment, especially in patients with higher leukocytosis or a high tumour burden.
TLS ennetamiseks ja raviks peab BLINCYTO’ga ravimise ajal rakendama asjakohaseid profülaktilisi meetmeid, k.a agressiivne hüdratsioon ja anti-hüperurikeemiline ravi (nt allopurinooli või rasburikaasiga), eriti kõrgema leukotsütoosi või kõrge kasvajakoormusega patsientidel.
Appropriate screening tests (i.e. tuberculin skin test and chest X-ray) should be performed in all patients (local recommendations may apply).
Kõigile patsientidele tuleb teha vajalikud sõeluuringud, näiteks tuberkuliintest ja röntgenülesvõte rindkerest (kehtida võivad kohalikud soovitused).
Appropriate screening tests, i.e. tuberculin skin test and chest X-ray, should be performed in all patients (local recommendations may apply).
Kõikidele patsientidele tuleb teha vastavad analüüsid – tuberkuliini nahatest ja rindkere röntgen (siia võivad lisanduda kohalikud soovitused).
Appropriate screening tests, i.e., tuberculin skin test and chest X-ray, should be performed in all patients (local recommendations may apply).
Kõikidel patsientidel tuleb teha nõuetekohased skriinimisanalüüsid, s.t tuberkuliini nahatest ja rindkere röntgenuuring (võivad olla kohaldatavad kohalikud soovitused).
Appropriate supportive medicinal products should be readily available in case of severe hypersensitivity reactions.
Tõsiste ülitundlikkusreaktsioonide tekke ohu tõttu peavad kohased toetavad ravimid olema käepärast.
Appropriate supportive therapies should be readily available in case of a severe hypersensitivity reaction.
Vahetult peavad olema kättesaadavad raskete ülitundlikkusreaktsioonide raviks vajalikud vahendid.
Appropriate techniques for self administration of Stelara, including use of the prefilled syringes.
Stelara isemanustamise asjakohased tehnikad, sh süstlite kasutamine.
Appropriate treatment should be promptly instituted, if indicated.
Vajadusel tuleb koheselt rakendada asjakohaseid ravimeetmeid.
Appropriate vaccination (hepatitis A and B) should be considered for patients in regular/repeated receipt of human plasma-derived C1 inhibitor product.
Patsientide puhul, kes kasutavad regulaarselt või korduvalt inimese vereplasmast valmistatud C1 inhibiitori tooteid, tuleb kaaluda sobivat vaktsineerimist (A- ja B-hepatiit).
Appropriate vaccination (hepatitis A and B) should be considered for patients in regular/repeated receipt of plasma-derived factor IX concentrates.
Plasmast pärineva IX faktori kontsentraati regulaarselt/korduvalt manustavatele patsientidele peab kaaluma vastava (hepatiit A ja B) vaktsineerimise tegemist.
appropriate.
asjakohane.
appropriately.
ANTIDEPRESSANDID
appropriately.
asjakohaselt jälgida.
Approved dose in patients undergoing percutaneous coronary intervention (PCI): The licensed and approved dosing regimen of Angiox is an intravenous (IV) bolus injection of 0.75 mg/kg body weight followed immediately by an intravenous infusion at 1.75 mg/kg/hour for at least the duration of the PCI.
Heakskiidetud annus perkutaanse koronaarse interventsiooni (PKI) korral: Angiox’i heakskiidetud annustamisskeem on 0,75 mg/kg kehakaalu kohta intravenoosse boolussüstena, millele järgneb kohe intravenoosne infusioon kiirusega 1,75 mg/kg kehakaalu kohta tunnis vähemasti protseduuri kestuse vältel.
Approved food additive (E 260), CR No 2034/96
Lubatud toidulisand (E 260), CR No 2034/96
Approved food additive (E 262), CR No 2034/96
Lubatud toidulisand (E 262), CR No 2034/96
Approx 15.0 mm x 8.0 mm, white, film coated, ovaloid, biconvex beveled edge tablet debossed with 'MLR4' on one side of the tablet and plain on the other side.
Ligikaudu 15,0 mm×8,0 mm valge polümeerikattega ovaalne kaksikkumer viltuse otsaga tablett, mille ühele küljele on pressitud “MLR4” ja teine külg on tühi.
Approx 18.8 mm x 10.0 mm, white, film coated, ovaloid, biconvex beveled edge tablet debossed with 'MLR3' on one side of the tablet and plain on the other side.
Ligikaudu 18,8 mm×10,0 mm valge polümeerikattega ovaalne kaksikkumer viltuse otsaga tablett, mille ühele küljele on pressitud “MLR3” ja teine külg on tühi.
Approx. how much insulin is
Järele- jäänud insuliini ligikaudne
Approx. how much solution is left
lahuse umbkaudne kogus
Approximate ceftaroline concentration (mg/ml)
Tseftaroliini ligikaudne kontsentratsioon (mg/ml)
Approximate guidelines for initial, pre-meal EXUBERA doses, based on patient body weight, are indicated in Table 1:
Tabelis 1 on toodud ligikaudsed juhised EXUBERA enne sööki manustatavate algannuste kohta, põhinedes patsiendi kehakaalul.
Approximate IU Dose
Ligikaudne annus IU-des
Approximate IU Dose
Ligikaudne annus RÜ-des
Approximate tablet dimensions 13.1 mm x 5.2 mm
Tableti ligikaudsed mõõtmed on 13,1 mm x 5,2 mm.
Approximately 1% of tenofovir disoproxil fumarate-treated adult patients discontinued treatment due to the gastrointestinal events.
Umbes 1% tenofoviirdisoproksiilfumaraadiga ravitud täiskasvanud patsientidest katkestas ravi seedetrakti kõrvalnähtude tõttu.
Approximately 1%, 46%, 53%, and 1% of patients were in WHO FC I, II, III and IV, respectively, at baseline.
Maailma Terviseorganisatsiooni määratluse järgi kuulus algtasemel I, II , III ja IV funktsionaalsesse klassi vastavalt ligikaudu 1%, 46%, 53% ja 1% patsientidest.
Approximately 10% of patients (10.4% and 9.8% of patients treated with the placebo/FOLFIRI and ZALTRAP/FOLFIRI regimens, respectively) received prior oxaliplatin-based adjuvant chemotherapy and progressed on or within 6 months of completion of adjuvant chemotherapy.
Ligikaudu 10% patsientidest (10,4% patseebo/FOLFIRI rühmas ja 9,8% ZALTRAP/FOLFIRI rühmas) olid eelnevalt saanud oksaliplatiinil põhinevat adjuvantset keemiaravi ning nende haigus oli progresseerunud adjuvantse keemiaravi ajal või 6 kuu jooksul pärast selle lõpetamist.
Approximately 10-20% is excreted in urine.
Umbes 10–20% eritub uriiniga.
Approximately 10–20% is excreted in urine.
Umbes 10...20% eritub uriiniga.
Approximately 12 % of children treated with interferon alfa-2b and ribavirin combination therapy developed increase in thyroid stimulating hormone (TSH).
Ligikaudu 12%-l alfa-2b-interferooni ja ribaviriini kombinatsioonraviga ravitud lastest tekkis TSH taseme tõus.
Approximately 12 to 21 % of children treated with ribavirin and interferon alfa-2b (pegylated and non pegylated) developed increase in thyroid stimulating hormone (TSH).
Ligikaudu 12 kuni 21%-l ribaviriini ja interferooniga alfa-2b (pegüleeritud ja mittepegüleeritud) ravitud lastest tekkis kilpnääret stimuleeriva hormooni (TSH) tõus.
Approximately 12 to 21% of children treated with ribavirin and interferon alfa-2b (pegylated and non pegylated) developed increase in thyroid stimulating hormone (TSH).
Ligikaudu 12 kuni 21%-l ribaviriini ja interferooniga alfa-2b (pegüleeritud ja mittepegüleeritud) ravitud lastest tekkis kilpnääret stimuleeriva hormooni (TSH) taseme tõus.
Approximately 12% of subjects in the Phase III study in patients with newly diagnosed CML in chronic phase and approximately 30% of subjects in the Phase II study in patients with imatinib- resistant or intolerant CML in chronic phase and accelerated phase were 65 years of age or over.
Ligikaudu 12% III faasi uuringus osalenud äsjadiagnoositud kroonilises faasis KML-ga patsientidest ja ligikaudu 30% II faasi uuringus osalenud patsientidest, kellel esines imatiniibi resistentsus või talumatus kroonilises- või aktseleratsioonifaasis KML korral, olid 65-aastased või vanemad.
Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month 3 and month 6 compared to fewer than 5% of subjects in the placebo arm.
Ligikaudu 15% patsientidest, kellele manustati Enbreli, saavutasid ACR 70 ravivastuse 3 ja 6kuu vältel, võrreldes vähem kui 5% platseebot saanud patsientidega.
Approximately 15% of the administered TRISENOX dose is excreted in the urine as unchanged AsIII.
Ligikaudu 15% manustatud TRISENOX’i annusest eritub uriiniga AsIII-na muutumatul kujul.
Approximately 17 % of cardiac dysfunction related events occurred after completion of Herceptin.
Ligikaudu 17% kardiaalse düsfunktsiooniga seotud juhtumitest ilmnesid pärast Herceptin-ravi lõppu.
Approximately 17 % of cardiac dysfunction related events occurred after completion of Herceptin.
Umbes 17% kardiaalse düsfunktsiooniga seotud juhtumitest ilmnesid pärast Herceptin- ravi lõppu.
Approximately 2.5 % of patients from the NCGS have experienced drug related adverse reactions.
Ligikaudu 2,5% patsientidest esines NCGS uuringu põhjal kõrvaltoimeid.
Approximately 2.8% (11/386 patients) of Perjeta-treated patients and 6.2% (23/372 patients) of placebo-treated patients tested positive for ATAs.
ATAde suhtes olid positiivsed umbes 2,8% (11/386) Perjeta’ga ravitud patsientidest ja 6,2% (23/372) platseebot saanud patsientidest.
Approximately 20 % was excreted as total topotecan and 2 % was excreted as N-desmethyl topotecan in the urine.
Umbes 20 % eritus muutumatul kujul topotekaanina ja 2 % N-desmetüültopotekaanina uriiniga.
Approximately 21 % of children treated with PegIntron/ribavirin combination therapy developed increase in thyroid stimulating hormone (TSH).
Ligikaudu 21%-l PegIntron’i/ribaviriini kombinatsiooniga ravitud lastest tekkis kilpnääret stimuleeriva hormooni (TSH) taseme tõus.
Approximately 21 % of children treated with ViraferonPeg/ribavirin combination therapy developed increase in thyroid stimulating hormone (TSH).
Ligikaudu 21%-l ViraferonPeg’i/ribaviriini kombinatsiooniga ravitud lastest tekkis kilpnääret stimuleeriva hormooni (TSH) taseme tõus.
Approximately 22.2% of patients with solid tumours, including GIST and MRCC, who received sunitinib in clinical trials experienced pulmonary events.
Ligikaudu 22,2%-l tihkete tuumoritega patsientidest (sealhulgas GISTiga ja MRCCga patsiendid), kes said kliinilistes uuringutes sunitiniibi, täheldati kopsutüsistusi.
Approximately 22.4% of patients treated with Sivextro in Phase 3 clinical studies (n= 662) experienced at least one treatment-emergent adverse reaction.
Ligikaudu 22,4% patsientidest, keda raviti III faasi kliinilistes uuringutes Sivextroga (n=662), tekkis vähemalt üks raviga seotud kõrvaltoime.
Approximately 22.4% of patients treated with Sivextro in Phase 3 clinical studies (n=662) experienced at least one treatment-emergent adverse reaction.
Ligikaudu 22,4% patsientidest, keda raviti III faasi kliinilistes uuringutes Sivextroga (n=662), tekkis vähemalt üks raviga seotud kõrvaltoime.
Approximately 24 - 72 hours after injection, a finger extension procedure may be performed, as necessary, to facilitate cord disruption.
Ligikaudu 24…72 tundi pärast süste tegemist võib vajaduse korral teha sõrmevenitusprotseduuri, et väädi katkemist hõlbustada.
Approximately 25 % of patients treated with Taltz achieved a PASI score < 5 by Week 2, more than 55 % achieved the PASI score < 5 by Week 4, and increased to 85 % by Week 12 (compared to 3 %, 14 % and 50 % for etanercept).
Ligikaudu 25 % Taltz’iga ravi saanud patsientidest saavutas PASI skoori < 5 2. nädalaks, enam kui 55 % saavutas PASI skoori < 5 4. nädalaks ja see suurenes 85 %-ni 12. nädalaks (võrreldes 3 %, 14 % ja 50 % etanertsepti rühmas).
Approximately 30 % of patients will also experience reactions at the injection site, predominantly mild inflammation or erythema.
Ligikaudu 30% patsientidest tekivad ka süstekoha reaktsioonid, valdavalt kerge põletik või punetus.
Approximately 30 ml of water
Ligikaudu 30 ml vett
Approximately 30% of study participants carried diagnoses other than ALS and MS, including stroke, traumatic brain injury, Parkinson’s disease, Alzheimer’s disease and other dementia, primary lateral sclerosis, progressive bulbar palsy, and progressive supranuclear palsy.
Ligikaudu 30%-l uuringus osalejatest kaasus muu haigus kui amüotroofiline lateraalskeroos või hulgiskleroos, sealhulgas insult, traumaatiline ajuvigastus, Parkinsoni tõbi, Alzheimeri tõbi ja muu dementsus, primaarne lateraalne skleroos, progresseeruv bulbaarparalüüs ja progresseeruv supranukleaarparalüüs.
Approximately 30% of the medicinal product in the body was removed during a single 4-hour dialysis session.
Ühe 4-tunnise dialüüsi käigus väljus ligikaudu 30% organismis sisalduvast ravimist.
Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)].
Ligikaudu 33% irbesartaani grupi patsientidest esines esmane liit- tulemusnäitaja, võrreldes 39% ja 41% platseebo ja amlodipiini grupis [suhtelise riski alanemine 20% võrreldes platseeboga (p = 0,024) ja suhtelise riski alanemine 23% võrreldes amlodipiiniga (p = 0,006)].
Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)].
Ligikaudu 33% irbesartaani grupi patsientidest esines esmane liit- tulemusnäitaja, võrreldes 39% ja 41% platseebo ja amlodipiini grupis suhtelise riski alanemine 20% vs platseebo (p = 0,024) ja suhtelise riski alanemine 23% võrreldes amlodipiiniga (p = 0,006).
Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)].
Ligikaudu 33% irbesartaani grupi patsientidest esines esmane liit- tulemusnäitaja, võrreldes 39% ja 41% platseebo ja amlodipiini grupis suhtelise riski alanemine 20% võrreldes platseeboga (p = 0,024) ja suhtelise riski alanemine 23% võrreldes amlodipiiniga (p = 0,006).
Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)].
Ligikaudu 33% irbesartaani grupi patsientidest esines esmane liit-tulemusnäitaja, võrreldes 39% ja 41% platseebo ja amlodipiini grupis suhtelise riski alanemine 20% võrreldes platseeboga (p = 0,024) ja suhtelise riski alanemine 23% võrreldes amlodipiiniga (p = 0,006).
Approximately 33% of the administered radioactive dose was excreted in urine, mainly as
Umbes 33% manustatud radioaktiivsest annusest eritus uriiniga peamiselt
Approximately 35% of subjects were chronic kidney disease (CKD) stage 1, 48% CKD stage 2, and 17% CKD stage 3 (eGFRCKD-EPI).
Ligikaudu 35%- l uuringus osalejatest oli 1. astme krooniline neeruhaigus, 48%-l 2. aste ja 17%-l 3. aste (eGFRCKD-EPI).
Approximately 35% of subjects were chronic kidney disease (CKD) stage 1, 48% CKD stage 2, and 17% CKD stage 3 (eGFRCKD-EPI).
Ligikaudu 35%-l uuringus osalejatest oli 1. astme krooniline neeruhaigus, 48%-l 2. aste ja 17%-l 3. aste (eGFRCKD-EPI).
Approximately 35% of the 579 patients aged 4 years and over who received treatment with sapropterin dihydrochloride (5 to 20 mg/kg/day) in the clinical trials for Kuvan experienced adverse reactions.
Kõrvaltoimed tekkisid ligikaudu 35%-l 579 patsiendist vanuses 4 aastat ja vanemad, kes said kliinilistes uuringutes Kuvan’iga sapropteriinvesinikkloriidi 5...20 mg/kg/ööpäevas.
Approximately 37% of patients in clinical trials in type 1 Gaucher disease, and 58% of patients in a clinical trial in Niemann-Pick type C disease reported tremor on treatment.
Ligikaudu 37%-l kliinilistes uuringutes osalenud I tüüpi Gaucher’ tõvega patsientidest ja 58%-l C- tüüpi Niemanni-Picki tõve kliinilises uuringus osalenud patsientidest on ilmnenud ravi käigus värinaid.
Approximately 38% of the treated patients with a stoma (an artificial opening at the front of the abdomen to collect faeces or urine from the body) experienced stoma complications such as swelling of the stoma.
Ligikaudu 38% ravitud patsientidest, kellel oli stooma (väljaheite ja uriini kogumiseks kirurgiliselt tehtud ava kõhuseinas), kogesid stooma tüsistusi, nt selle paistetust.
Approximately 40% of patients (combined APEX and FACT) had a baseline sUA of ≥ 10 mg/dL.
Ligikaudu 40%-l patsientidest (APEX ja FACT kokku) oli ravi algul sUA ≥10 mg/dl.
Approximately 40-50 hours after PhotoBarr administration, light should be delivered by a fibre optic diffuser passed through the central channel of a centring balloon.
40…50 tundi pärast PhotoBarr’i manustamist suunatakse läbi tsentreeriva ballooni tsentraalse kanali viidud fiiberoptilise difuusori abil söögitorusse valgus.
approximately 48-fold.
48-kordne ↑, mille põhjuseks on
Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.
Ligikaudu 50% manustatud annusest eritub uriiniga ja ülejäänu väljaheitega.
Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.
Ligikaudu 50% manustatud annusest eritub uriiniga ja ülejäänud osa roojaga.
Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.
Ligikaudu 50% manustatud annusest väljub uriiniga ja ülejäänud osa väljaheitega.
Approximately 50 ml of water to prepare the suspension
Ligikaudu 50 ml vett suspensiooni valmistamiseks
Approximately 50-60% of an oral dose is excreted in the urine with the remainder eliminated in the faeces.
Ligikaudu 50–60% suukaudsest annusest eritub uriiniga ja ülejäänu väljaheitega.
Approximately 51 % was excreted as total topotecan and 3 % was excreted as N-desmethyl topotecan in the urine.
Ligikaudu 51 % eritus muutumatul kujul topotekaanina ja 3 % N- desmetüültopotekaanina uriiniga.
Approximately 51 % was excreted as total topotecan and 3 % was excreted as N-desmethyl topotecan in the urine.
Ligikaudu 51 % eritus muutumatul kujul topotekaanina ja 3 % N-desmetüültopotekaanina uriiniga.
Approximately 51% was excreted as total topotecan and 3 % was excreted as N-desmethyl topotecan in the urine.
Ligikaudu 51% eritus muutumatul kujul topotekaanina ja 3% N- desmetüültopotekaanina uriiniga.
Approximately 52% of the patients treated with Revestive experienced adverse reactions (versus 36% of the patients given placebo).
Kõrvaltoimeid täheldati ligikaudu 52%-l Revestive’iga ravitud patsientidest (võrrelduna 36%-ga patsientidest platseebogrupis).
Approximately 54% of patients initiating treatment at the recommended dose of 750 mg required at least one dose adjustment due to adverse reaction, with a median time to first dose reduction of approximately 7 weeks.
Ligikaudu 54% patsientidest, kes alustasid ravi soovitatavas annuses 750 mg, vajasid vähemalt ühte annuse kohandamist kõrvaltoimete tõttu, mediaanaeg esimese annuse vähendamiseni oli ligikaudu 7 nädalat.
Approximately 6% of patients treated with MIRCERA are expected to experience adverse reactions.
Kõrvaltoimete ilmnemist on oodata ligikaudu 6% MIRCERA’ga ravitud patsientidest.
Approximately 60% of cinacalcet-treated patients achieved a  30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels.
Ligikaudu 60% tsinakaltseediga ravitud patsientidest saavutati iPTH taseme langus  30% ja see efekt oli sarnane kogu iPTH lähteväärtuste spektri ulatuses.
Approximately 60% of cinacalcet-treated patients achieved a  30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels.
Ligikaudu 60% tsinakaltseediga ravitud patsientidest saavutati iPTH taseme langus 30%.
Approximately 60% of patients received 3-6 cycles of Arzerra and 32% received 7-12 cycles.
Ligikaudu 60% patsientidest said 3...6 tsüklit Arzerra’t ja 32% said 7...12 tsüklit.
Approximately 60-70% of the dose was recovered in the urine as active substance.
Ligikaudu 60–70% annusest eritub uriini aktiivse toimeainena.
Approximately 65% of an i.v. dose is renally excreted within the first 24 hours.
Ligikaudu 65% intravenoossest annusest eritub neerude kaudu esimese 24 tunni jooksul.
Approximately 68% of patients in Group A and 63% of patients in Group B had been treated with dabigatran 110 mg twice daily.
Ligikaudu 68% A rühma patsientidest ja 63% B rühma patsientidest oli ravitud dabigatraaniga annuses 110 mg kaks korda ööpäevas.
Approximately 6–16% of the administered dose was excreted in the urine as unchanged drug.
Umbes 6...16% manustatud annusest eritus uriiniga muutumatul kujul.
Approximately 7% of an oral dose is excreted as unchanged 6– mercaptopurine within 12 hours after administration.
Ligikaudu 7% suukaudsest annusest eritub esialgsel kujul 6-merkaptopuriinina 12 tunni jooksul pärast manustamist.
Approximately 7-8% of individuals of Caucasian descent, 3-6% of Black African descent, 2-3% of Arab descent and 1-2% of Asian descent generally lack the capacity to metabolize CYP2D6 substrates and are classified as Poor Metabolizer (PMs).
Ligikaudu 7…8%-l valgetest Euroopa päritolu isikutest, 3…6%-l Aafrika päritolu isikutest, 2…3%-l Araabia päritolu isikutest ja 1…2%-l Aasia päritolu isikutest puudub tavaliselt võime metaboliseerida CYP2D6 substraate ning neid nimetatakse aeglasteks metaboliseerijateks.
Approximately 70 % of patients treated with Rebif can expect to experience the typical interferon flu-like syndrome within the first six months after starting treatment.
Umbes 70% Rebif-ravi saanud patsientidest võib esimese 6 kuu jooksul pärast ravi alustamist esineda interferoon-ravile tüüpiline gripitaoline sündroom.
Approximately 70 patients from study EGF114299 who have been randomised to the lapatinib + AI arm with an exposure of approximately 6 months.
Ligikaudu 70 patsienti uuringust EGF114299, kes on randomiseeritud lapatiniibi + AI rühma ning see ravi on kestnud ligikaudu 6 kuud.